









Markets
/
Stocks
/
nasdaq-vnda
/

Vanda Pharmaceuticals Inc

VNDA

6.650USD

-0.260-3.76%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

187.71MMarket Cap

LossP/E TTM



Vanda Pharmaceuticals Inc

6.650

-0.260-3.76%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Vanda Pharmaceuticals Inc

Currency: USD Updated: 2026-03-27

Key Insights

Vanda Pharmaceuticals Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 64 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 15.50.In the medium term, the stock price is expected to remain stable.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Vanda Pharmaceuticals Inc's Score

Industry at a Glance

Industry Ranking

64 / 391

Overall Ranking

174 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

Vanda Pharmaceuticals Inc Highlights

StrengthsRisks

Vanda Pharmaceuticals Inc. is a global biopharmaceutical company focused on the development and commercialization of therapies to address unmet medical needs and improve the lives of patients. The Company’s commercial portfolio consist of three products: Fanapt for the acute treatment of manic or mixed episodes associated with bipolar I disorder and the treatment of schizophrenia, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) and for the treatment of nighttime sleep disturbances in Smith-Magenis syndrome (SMS) and PONVORY for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease. In addition, it has a number of drugs and/or additional indications for current products in development, including Bysanti, Tradipitant, Imsidolimab, VTR-297, VQW-765, and others. Bysanti is the active metabolite of Fanapt.

Fairly Valued

The company’s latest PE is -1.85, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 45.82M shares, decreasing 18.58% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 3.70M shares of this stock.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

15.500

Target Price

+117.70%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Vanda Pharmaceuticals Inc is 6.82, ranking 186 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 57.22M, representing a year-over-year increase of 7.58%, while its net profit experienced a year-over-year increase of 2774.33%.

Score

Industry at a Glance

Previous score

6.82

Change



Financials

6.16

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.81

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.28

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.73

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.13

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Vanda Pharmaceuticals Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Vanda Pharmaceuticals Inc is 8.84, ranking 12 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -1.85, which is -5807.61% below the recent high of 105.42 and -4035.88% above the recent low of -76.39.

Score

Industry at a Glance

Previous score

8.84

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 64/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Vanda Pharmaceuticals Inc is 7.50, ranking 289 out of 391 in the Biotechnology & Medical Research industry. The average price target is 11.00, with a high of 20.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

7.50

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 5 analysts

Buy

Current Rating

15.500

Target Price

+124.31%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Vanda Pharmaceuticals Inc

VNDA

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

IQVIA Holdings Inc

IQV

Beigene Ltd

ONC

Intellia Therapeutics Inc

NTLA

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Vanda Pharmaceuticals Inc is 6.73, ranking 151 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 8.99 and the support level at 5.78, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.87

Change

-0.14

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.475

Sell

RSI(14)

37.498

Neutral

STOCH(KDJ)(9,3,3)

7.301

Oversold

ATR(14)

0.523

Low Volatility

CCI(14)

-92.136

Neutral

Williams %R

97.419

Oversold

TRIX(12,20)

-0.263

Sell

StochRSI(14)

1.288

Sell

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

6.950

Sell

MA10

7.460

Sell

MA20

8.044

Sell

MA50

7.721

Sell

MA100

6.900

Sell

MA200

5.836

Buy

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Vanda Pharmaceuticals Inc is 7.00, ranking 85 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 77.53%, representing a quarter-over-quarter decrease of 1.37%. The largest institutional shareholder is The Vanguard, holding a total of 3.70M shares, representing 6.26% of shares outstanding, with 5.58% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

5.77M

-3.54%

The Vanguard Group, Inc.

Star Investors

3.56M

+0.40%

Renaissance Technologies LLC

Star Investors

3.48M

+0.85%

Polymeropoulos (Mihael Hristos)

2.34M

+0.43%

Acadian Asset Management LLC

2.23M

+28.69%

Dimensional Fund Advisors, L.P.

2.56M

-0.84%

Two Sigma Investments, LP

1.57M

+17.63%

Millennium Management LLC

3.25M

+4.18%

BlackRock Financial Management, Inc.

2.25M

-7.66%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Vanda Pharmaceuticals Inc is 3.75, ranking 120 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.69. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.